Abstract
Background: It has been shown that central urotensin II acts on the central nervous system to increase arterial pressure in conscious rats. Objective: To investigate the intracellular signal transduction mechanisms of the central cardiovascular action of urotensin II. Methods: The effects of intracerebroventricular (i.c.v.) administration of the extracellular signal-regulated protein kinase (ERK) inhibitor, PD 98059 (20 nmol), the phosphatidylinositol 3 (PI3) kinase inhibitor, wortmannin (20 nmol), or the Rho kinase inhibitor, Y-27632 (20 nmol), on cardiovascular responses to i.c.v. urotensin II (10 nmol) were determined in conscious rats. Results: I.c.v. injection of urotensin II increased both arterial pressure and heart rate (14.9 ± 1.5 mmHg and 94.6 ± 12.8 beats/min, respectively; P < 0.05 for each). Pretreatment with PD 98059 or Y-27632 significantly (P < 0.01 and P < 0.05, respectively) attenuated the pressor response induced by i.c.v. urotensin II (6.6 ± 1.4 and 6.9 ± 1.2 mmHg, respectively). Pretreatment with a mixed solution of PD 98059 and Y-27632 failed to cause further suppression of the urotensin II-induced pressor responses (4.5 ± 0.9 mmHg). In contrast, pretreatment with i.c.v. wortmannin failed to influence the pressor response induced by i.c.v. urotensin II (12.6 ± 1.3 mmHg). The tachycardiac response induced by i.c.v. urotensin II was not influenced by pretreatment with PD 98059, Y-27632 or wortmannin. Conclusions: These findings suggest that the ERK and Rho kinase pathways, but not the PI3 pathway, may be involved in the central pressor action of urotensin II in conscious rats.
| Original language | English |
|---|---|
| Pages (from-to) | 983-988 |
| Number of pages | 6 |
| Journal | Journal of hypertension |
| Volume | 22 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 1 2004 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Physiology
- Cardiology and Cardiovascular Medicine
Cite this
Role of ERK and Rho kinase pathways in central pressor action of urotensin II. / Lin, Yingzi; Matsumura, Kiyoshi; Tsuchihashi, Takuya; Fukuhara, Masayo; Fujii, Koji; Iida, Mitsuo.
In: Journal of hypertension, Vol. 22, No. 5, 01.05.2004, p. 983-988.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Role of ERK and Rho kinase pathways in central pressor action of urotensin II
AU - Lin, Yingzi
AU - Matsumura, Kiyoshi
AU - Tsuchihashi, Takuya
AU - Fukuhara, Masayo
AU - Fujii, Koji
AU - Iida, Mitsuo
PY - 2004/5/1
Y1 - 2004/5/1
N2 - Background: It has been shown that central urotensin II acts on the central nervous system to increase arterial pressure in conscious rats. Objective: To investigate the intracellular signal transduction mechanisms of the central cardiovascular action of urotensin II. Methods: The effects of intracerebroventricular (i.c.v.) administration of the extracellular signal-regulated protein kinase (ERK) inhibitor, PD 98059 (20 nmol), the phosphatidylinositol 3 (PI3) kinase inhibitor, wortmannin (20 nmol), or the Rho kinase inhibitor, Y-27632 (20 nmol), on cardiovascular responses to i.c.v. urotensin II (10 nmol) were determined in conscious rats. Results: I.c.v. injection of urotensin II increased both arterial pressure and heart rate (14.9 ± 1.5 mmHg and 94.6 ± 12.8 beats/min, respectively; P < 0.05 for each). Pretreatment with PD 98059 or Y-27632 significantly (P < 0.01 and P < 0.05, respectively) attenuated the pressor response induced by i.c.v. urotensin II (6.6 ± 1.4 and 6.9 ± 1.2 mmHg, respectively). Pretreatment with a mixed solution of PD 98059 and Y-27632 failed to cause further suppression of the urotensin II-induced pressor responses (4.5 ± 0.9 mmHg). In contrast, pretreatment with i.c.v. wortmannin failed to influence the pressor response induced by i.c.v. urotensin II (12.6 ± 1.3 mmHg). The tachycardiac response induced by i.c.v. urotensin II was not influenced by pretreatment with PD 98059, Y-27632 or wortmannin. Conclusions: These findings suggest that the ERK and Rho kinase pathways, but not the PI3 pathway, may be involved in the central pressor action of urotensin II in conscious rats.
AB - Background: It has been shown that central urotensin II acts on the central nervous system to increase arterial pressure in conscious rats. Objective: To investigate the intracellular signal transduction mechanisms of the central cardiovascular action of urotensin II. Methods: The effects of intracerebroventricular (i.c.v.) administration of the extracellular signal-regulated protein kinase (ERK) inhibitor, PD 98059 (20 nmol), the phosphatidylinositol 3 (PI3) kinase inhibitor, wortmannin (20 nmol), or the Rho kinase inhibitor, Y-27632 (20 nmol), on cardiovascular responses to i.c.v. urotensin II (10 nmol) were determined in conscious rats. Results: I.c.v. injection of urotensin II increased both arterial pressure and heart rate (14.9 ± 1.5 mmHg and 94.6 ± 12.8 beats/min, respectively; P < 0.05 for each). Pretreatment with PD 98059 or Y-27632 significantly (P < 0.01 and P < 0.05, respectively) attenuated the pressor response induced by i.c.v. urotensin II (6.6 ± 1.4 and 6.9 ± 1.2 mmHg, respectively). Pretreatment with a mixed solution of PD 98059 and Y-27632 failed to cause further suppression of the urotensin II-induced pressor responses (4.5 ± 0.9 mmHg). In contrast, pretreatment with i.c.v. wortmannin failed to influence the pressor response induced by i.c.v. urotensin II (12.6 ± 1.3 mmHg). The tachycardiac response induced by i.c.v. urotensin II was not influenced by pretreatment with PD 98059, Y-27632 or wortmannin. Conclusions: These findings suggest that the ERK and Rho kinase pathways, but not the PI3 pathway, may be involved in the central pressor action of urotensin II in conscious rats.
UR - http://www.scopus.com/inward/record.url?scp=2542449375&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2542449375&partnerID=8YFLogxK
U2 - 10.1097/00004872-200405000-00021
DO - 10.1097/00004872-200405000-00021
M3 - Article
C2 - 15097239
AN - SCOPUS:2542449375
VL - 22
SP - 983
EP - 988
JO - Journal of Hypertension
JF - Journal of Hypertension
SN - 0263-6352
IS - 5
ER -